Terms: = Cervical cancer AND HER1, YOR227W AND Treatment
2 results:
1. Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts.
Birle DC; Hedley DW
Mol Cancer Ther; 2006 Oct; 5(10):2494-502. PubMed ID: 17041093
[TBL] [Abstract] [Full Text] [Related]
2. Enhanced sensitivity to the her1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract] [Full Text] [Related]